Plain-language summary, compiled from the cited regulatory records
Metoclopramide is a medication classified as a propulsive agent [1]. It is approved for short-term therapy in adults experiencing symptomatic, documented gastroesophageal reflux who have not responded to standard treatments [1]. This therapy is typically recommended for a duration of 4 to 12 weeks [1]. Metoclopramide primarily addresses daytime and post-meal heartburn symptoms, with a less pronounced effect on nighttime symptoms [1].
In the past 12 months, there have been 2,623 adverse event reports associated with metoclopramide [2]. Common reactions reported include nausea, off-label use, fatigue, vomiting, and diarrhea [2]. Metoclopramide is available under various brand names in this market.
This is not medical advice. Consult a qualified healthcare professional.
GBOfficial regulatory label· revised May 29, 2026[1]
Adult population Metoclopramide is indicated in adults for: - Prevention of delayed chemotherapy induced nausea and vomiting (CINV) - Prevention of radiotherapy induced nausea and vomiting (RINV). - Symptomatic treatment of nausea and vomiting, including acute migraine induced nausea and vomiting.
Metoclopramide can be used in combination with oral analgesics to improve the absorption of analgesics in acute migraine.
Diagnostic procedures:
Radiology, Duodenal intubation 'Metoclopramide' speeds up the passage of a barium meal by increasing the rate of gastric emptying, co-ordinating peristalsis and dilating the duodenal bulb. 'Metoclopramide' also facilitates duodenal intubation procedures.
Paediatric population Metoclopramide is indicated in children (aged 1-18 years) for: - Prevention of delayed chemotherapy induced nausea and vomiting (CINV) as a second line option.
USUnited States· FDA
4 products
Uses
USOfficial regulatory label· revised May 27, 2026[2]
1 INDICATIONS AND USAGE Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. Relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
4 ) ].
Metoclopramide tablets are indicated for the:
Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. ( 1 ) Relief of symptoms in adults with acute and recurrent diabetic gastroparesis. ( 1 ) Limitations of Use : Metoclopramide tablets are not recommended for use in pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates.
4 )
CACanada· Health Canada
4 products
How to take
CAOfficial regulatory label· revised March 22, 2025[3]
5 mg/kg BODY WEIGHT.
As an Adjunct in the Management of Delayed Gastric Emptying Adults:
When parenteral administration is required, 2 mL (10 mg) IM or IV (slowly) 2 or 3 times daily as needed.
For the Prophylaxis of Cisplatin-Induced Vomiting Adults:
For the patients treated with cisplatin in doses up to and including 100 mg/m2, Metoclopramide Hydrochloride Injection may be administered by infusion after dilution (See Intravenous Infusion) in single doses of 1 mg/kg of body weight.
For patients treated with cisplatin doses greater than 100 mg/m2, the single recommended dose may be increased to 2 mg/kg body weight administered by infusion. Infuse slowly over a 15-minute period and repeat the dose every 2 hours for two doses, then every 3 hours for three doses.
Drug interactions
Known interactions involving Metoclopramide. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 600. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
[2]FDA DailyMed · 15d616d7-2f4c-48… · revised May 27, 2026 [PDF]
[3]Health Canada (DPD) · 02185431 · revised March 22, 2025
[4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.
How to take
GBOfficial regulatory label· revised May 29, 2026[1]
Posology Adult patients The recommended single dose is 10 mg, repeated up to three times daily. 5mg/kg body weight. The maximum recommended treatment duration is 5 days. 3). 15 mg/kg body weight, repeated up to three times daily by oral route.
5 mg/kg body weight. Dosing table The maximum treatment duration is 5 days for prevention of delayed chemotherapy induced nausea and vomiting (CINV). Metoclopramide tablets are not suitable for use in children weighing less than 61 kg.
5 mg Up to 3 times daily 9-18 years 30-60 kg 5 mg Up to 3 times daily 15-18 years Over 60kg 10 mg Up to 3 times daily Other pharmaceutical forms/strengths may be more appropriate for administration to this population. Special population Elderly In elderly patients a dose reduction should be considered, based on renal and hepatic function and overall frailty.
Renal impairment:
In patients with end stage renal disease (Creatinine clearance ≤ 15 ml/min), the daily dose should be reduced by 75%. 2). 2). Other pharmaceutical forms/strengths may be more appropriate for administration to these populations.
Diagnostic indications:
A single dose of 'Metoclopramide' may be given 5-10 minutes before the examination, subject to body weight consideration, (see above). 3). 4).
This is not medical advice. Consult a qualified healthcare professional.
Side effects & warnings
GBOfficial regulatory label· Adverse reactions· revised May 29, 2026[1]
Adverse reactions listed by System Organ Class. Frequencies are defined using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10000 to <1/1000), very rare (<1/10000), not known (cannot be estimated from the available data).
3); Transient increase in blood pressure. *Endocrine disorders during prolonged treatment in relation with hyperprolactinaemia (amenorrhoea, galactorrhoea, gynaecomastia). 4). - Drowsiness, decreased level of consciousness, confusion, hallucination.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
GBOfficial regulatory label· Warnings and precautions· revised May 29, 2026[1]
g. cerebral irritation. Neurological Disorders Extrapyramidal disorders may occur, particularly in children and young adults, and/or when high doses are used. These reactions occur usually at the beginning of the treatment and can occur after a single administration.
Metoclopramide should be discontinued immediately in the event of extrapyramidal symptoms. These effects are generally completely reversible after treatment discontinuation, but may require a symptomatic treatment (benzodiazepines in children and/or anticholinergic anti- Parkinsonian medicinal products in adults).
2 should be respected between each metoclopramide administration, even in case of vomiting and rejection of the dose, in order to avoid overdose. Prolonged treatment with metoclopramide may cause tardive dyskinesia, potentially irreversible, especially in the elderly.
8). Treatment must be discontinued if clinical signs of tardive dyskinesia appear. 8). Metoclopramide should be discontinued immediately in the event of symptoms of neuroleptic malignant syndrome and appropriate treatment should be initiated.
3) Symptoms of Parkinson’s disease may also be exacerbated by metoclopramide. Methemoglobinemia Methemoglobinemia which could be related to NADH cytochrome b5 reductase deficiency has been reported. In such cases, metoclopramide should be immediately and permanently discontinued and appropriate measures initiated (such as treatment with methylene blue).
8). Special care should be taken when administering metoclopramide, particularly via the intravenous route to the elderly population, to patients with cardiac conduction disturbances (including QT prolongation), patients with uncorrected electrolyte imbalance, bradycardia and those taking other drugs known to prolong QT interval.
g. hypotension, akathisia). 2). Metoclopramide may cause elevation of serum prolactin levels. Care should be exercised when using metoclopramide in patients with a history of atopy (including asthma) or porphyria. Metoclopramide should not be used in the immediate post-operative period (up to 3- 4 days) following pyloroplasty or gut anastomosis, as vigorous gastrointestinal contractions may adversely affect healing.
Special care should be taken when administering metoclopramide intravenously to patients with “sick sinus syndrome” or other cardiac conduction disturbances. There have been very rare reports of abnormalities of cardiac conduction with intravenous metoclopramide.
Metoclopramide should be used with care with other drugs affecting cardiac conduction.
This is not medical advice. Consult a qualified healthcare professional.
Who should not take it
GBOfficial regulatory label· Contraindications· revised May 29, 2026[1]
5) • Known history of methaemoglobinaemia with metoclopramide or of NADH cytochrome-b5 deficiency. 4) Metoclopramide should not be used during the first three to four days following operations such as pyloroplasty or gut anastomosis as vigorousmuscular contractions may not help healing.
This is not medical advice. Consult a qualified healthcare professional.
USOfficial regulatory label· revised May 27, 2026[2]
2 ) Administer metoclopramide continuously or intermittently: Continuous: Administer 10 to 15 mg, 30 minutes before each meal and at bedtime (maximum of 60 mg per day) for 4 to 12 weeks.
Intermittent:
Single doses up to 20 mg prior to provoking situation. 3 ) For gastroesophageal reflux and acute and recurrent diabetic gastroparesis, see Full Prescribing Information for recommended dosage reductions for elderly patients, in patients with moderate or severe hepatic or renal impairment, and cytochrome P450 2D6 (CYP2D6) poor metabolizers.
1 ) ]. 2 Dosage for Gastroesophageal Reflux Metoclopramide tablets may be administered continuously or intermittently in patients with symptomatic gastroesophageal reflux who fail to respond to conventional therapy: Continuous Dosing The recommended adult dosage of metoclopramide is 10 to 15 mg four times daily for 4 to 12 weeks.
The treatment duration is determined by endoscopic response. Administer the dosage thirty minutes before each meal and at bedtime. The maximum recommended daily dosage is 60 mg. Table 1 displays the recommended daily dosage and maximum daily dosage for adults and dosage adjustments for patients with moderate or severe hepatic impairment (Child-Pugh B or C), in patients with creatinine clearance less than 60 mL/minute, in cytochrome P450 2D6 (CYP2D6) poor metabolizers, and with concomitant use with strong CYP2D6 inhibitors.
Intermittent Dosing If symptoms only occur intermittently or at specific times of the day, administer metoclopramide in single dose up to 20 mg prior to the provoking situation. Consider dosage reductions for the populations and situations in Table 1.
Table 1. 6 ) ] 5 mg four times daily (thirty minutes before each meal and at bedtime) or 10 mg twice daily 20 mg 1 Elderly patients may be more sensitive to the therapeutic or adverse effects of metoclopramide; therefore, consider a lower starting dosage of 5 mg four times daily with titration to the recommended adult dosage of 10 to 15 mg four times daily based upon response and tolerability.
3 Dosage for Acute and Recurrent Diabetic Gastroparesis The recommended adult dosage for the treatment of acute and recurrent diabetic gastroparesis is 10 mg four times daily for 2 to 8 weeks, depending on symptomatic response. 1 ) ].
Administer the dosage thirty minutes before each meal and at bedtime. The maximum recommended daily dosage is 40 mg. Table 2 displays the recommended daily dosage and maximum daily dosage for adults and dosage adjustments for patients with moderate or severe hepatic impairment (Child-Pugh B or C), in patients with creatinine clearance less than 60 mL/minute, in cytochrome P450 2D6 (CYP2D6) poor metabolizers, and with concomitant use with strong CYP2D6 inhibitors.
If patients with diabetic gastroparesis have severe nausea or vomiting and are unable to take oral metoclopramide tablets, consider starting therapy with metoclopramide injection given intramuscularly or intravenously for up to 10 days (see the prescribing information for metoclopramide injection).
After patients are able to take oral therapy, switch to metoclopramide tablets. Table 2. 6 ) ] 5 mg twice daily 10 mg 1 Elderly patients may be more sensitive to the therapeutic or adverse effects of metoclopramide; therefore, consider a lower dosage of 5 mg four times daily with titration to the recommended adult dosage of 10 mg four times daily based upon response and tolerability.
This is not medical advice. Consult a qualified healthcare professional.
Most-reported reactions to the US regulator (12 mo to June 4, 2026): 2,623 reports total. [4]
Nausea 348
Off Label Use 287
Fatigue 241
Vomiting 237
Diarrhoea 230
Drug Ineffective 169
Headache 160
Constipation 146
Abdominal Pain 125
Decreased Appetite 125
Dyspnoea 119
Pyrexia 115
Side effects & warnings
USOfficial regulatory label· Adverse reactions· revised May 27, 2026[2]
8 ) ] The following adverse reactions have been identified from clinical studies or postmarketing reports of metoclopramide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The most common adverse reactions (in approximately 10% of patients receiving 10 mg of metoclopramide four times daily) were restlessness, drowsiness, fatigue, and lassitude. In general, the incidence of adverse reactions correlated with the dosage and duration of metoclopramide administration.
Adverse reactions, especially those involving the nervous system, occurred after stopping metoclopramide including dizziness, nervousness, and headaches. Central Nervous System Disorders Tardive dyskinesia, acute dystonic reactions, drug-induced parkinsonism, akathisia, and other extrapyramidal symptoms Convulsive seizures Hallucinations Restlessness, drowsiness, fatigue, and lassitude occurred in approximately 10% of patients who received 10 mg four times daily.
Insomnia, headache, confusion, dizziness, or depression with suicidal ideation occurred less frequently. Neuroleptic malignant syndrome, serotonin syndrome (in combination with serotonergic agents).
Endocrine Disorders :
Fluid retention secondary to transient elevation of aldosterone. , jaundice and altered liver function tests, when metoclopramide was administered with other drugs with known hepatotoxic potential Renal and Urinary Disorders : Urinary frequency, urinary incontinence Hematologic Disorders : Agranulocytosis, neutropenia, leukopenia, methemoglobinemia, sulfhemoglobinemia Hypersensitivity Reactions : Bronchospasm (especially in patients with a history of asthma), urticaria; rash; angioedema, including glossal or laryngeal edema Eye Disorders : Visual disturbances Metabolism Disorders : Porphyria Most common adverse reactions (> 10%) are restlessness, drowsiness, fatigue, and lassitude.
gov/medwatch.
USOfficial regulatory label· Warnings and precautions· revised May 27, 2026[2]
5 WARNINGS AND PRECAUTIONS Tardive Dyskinesia (TD), Other Extrapyramidal Symptoms (EPS), and Neuroleptic Malignant Syndrome (NMS) : Avoid concomitant use of other drugs known to cause TD/EPS/NMS and avoid use in patients with Parkinson’s Disease.
If symptoms occur, discontinue metoclopramide and seek immediate medical attention. 2 ) Depression and suicidal ideation/suicide : Avoid use. 1 Tardive Dyskinesia Metoclopramide can cause tardive dyskinesia (TD), a syndrome of potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities.
Movements may be choreoathetotic in appearance. The risk of developing TD and the likelihood that TD will become irreversible increases with duration of treatment and total cumulative dosage. 5 ) ], and in patients with diabetes mellitus.
3 ) ]. Discontinue metoclopramide immediately in patients who develop signs and symptoms of TD. There is no known effective treatment for established cases of TD, although in some patients TD may remit, partially or completely, within several weeks to months after metoclopramide is withdrawn.
Metoclopramide itself may suppress, or partially suppress, the signs of TD, thereby masking the underlying disease process. The effect of this symptomatic suppression upon the long-term course of TD is unknown. Metoclopramide is contraindicated in patients with a history of TD [ see Contraindications ( 4 ) ].
, antipsychotics). 2 Other Extrapyramidal Symptoms In addition to TD, metoclopramide may cause other extrapyramidal symptoms (EPS), parkinsonian symptoms, and motor restlessness. Advise patients to seek immediate medical attention if such symptoms occur and to discontinue metoclopramide.
Extrapyramidal symptoms (EPS), such as acute dystonic reactions, occurred in patients treated with metoclopramide dosages of 30 mg to 40 mg daily. Such reactions occurred more frequently in adults less than 30 years of age and at higher than recommended dosages.
EPS occurred more frequently in pediatric patients compared to adults (metoclopramide is not approved for use in pediatric patients). Symptoms can occur in the first 24 to 48 hours after starting metoclopramide. Symptoms included involuntary movements of limbs and facial grimacing, torticollis, oculogyric crisis, rhythmic protrusion of tongue, bulbar type of speech, trismus, or dystonic reactions resembling tetanus.
This is not medical advice. Consult a qualified healthcare professional.
Who should not take it
USOfficial regulatory label· Contraindications· revised May 27, 2026[2]
2 ) ]. , in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation). In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. 5 ) ]. In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures [ see Adverse Reactions ( 6 ) ].
In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm [ see Adverse Reactions ( 6 ) ]. History of TD or dystonic reaction to metoclopramide ( 4 ) When stimulation of gastrointestinal motility might be dangerous ( 4 ) Pheochromocytoma, catecholamine-releasing paragangliomas ( 4 ) Epilepsy ( 4 ) Hypersensitivity to metoclopramide ( 4 )
This is not medical advice. Consult a qualified healthcare professional.
(When the 2 mg/kg dose is used, the last dose may be omitted).
For the Prophylaxis of Postoperative Vomiting Adults:
Administer 2 mL (10 mg) intramuscularly near the end of surgery. g. general anesthesia of 2 hours or more, abdominal or pelvic surgery with visceral manipulation, absence of gastric suction). Dosing may be repeated every 4 to 6 hours.
For Small Bowel Intubations:
Adults: 10 mg by IV route (slowly) preferably at the time when the tip of the tube reaches the pyloric region.
Children:
Single dose of 100 mcg/kg IV slowly. , therapy should be initiated at approximately one-half the recommended dosage. Depending upon clinical efficacy and safety considerations, the dosage may be increased or decreased as appropriate.
See OVERDOSAGE section for information regarding dialysis. Metoclopramide undergoes minimal hepatic metabolism, except for simple conjugation. Its safe use has been described in patients with advanced liver disease whose renal function was normal.
Metoclopramide Hydrochloride Injection Page 9 of 18 PHARMACEUTICAL INFORMATION Drug Substance Proper Name: Metoclopramide hydrochloride Chemical Name: {4-amino-5-chloro-N-[(2-diethylamino)ethyl]-2- methoxybenzamide}monohydrochloride monohydrate.
33 g/mL). 5- 184ºC. 3. 5. Composition Metoclopramide Hydrochloride Injection is a sterile solution in single dose glass vials. 5 with hydrochloric acid and/or sodium hydroxide. Metoclopramide Hydrochloride Injection is preservative free.
STORAGE AND STABILITY Store between 15 and 30ºC. Protect from light. Discard unused portion. Intravenous Infusion The 10 mL single use vial containing 50 mg (5 mg/mL) of metoclopramide hydrochloride and the 30 mL single use vial containing 150 mg (5 mg/mL) of metoclopramide hydrochloride are intended for IV infusion after dilution.
45% Injection Solutions of metoclopramide that have been prepared by dilution of the injection with 50 mL of one of these compatible IV solutions are stable for up to 48 hours when stored at room temperature and exposed to normal light conditions.
Warning:
As with all parenteral drug products, IV admixtures should be inspected visually for clarity, particulate matter, precipitate, discolouration and leakage prior to administration, whenever solution and container permit. Solutions showing haziness, particulate matter, precipitate, discolouration or leakage should not be used.
AVAILABILITY OF DOSAGE FORMS Metoclopramide Hydrochloride Injection is available in single use amber glass vials in boxes of 10 x 2 mL, 5 x 10 mL and 1 x 30 mL. DETAILED PHARMACOLOGY Metoclopramide is a dopamine antagonist which appears to block preferentially the D-2 (non- adenylate cyclase linked) receptors.
In the rat, metoclopramide antagonizes apomorphine-induced stereotype, causes catalepsy, elevates prolactin, aldosterone and plasma renin levels, and enhances dopamine turnover in mesolimbic and striatal structures. Metoclopramide antagonizes in vitro the dopamine-induced inhibition of potassium-evoked 3H- acetylcholine release in striatal structures.
In the rat, parenteral administration of metoclopramide decreases striatal acetylcholine levels. The extrapyramidal side effects caused by metoclopramide and other neuroleptics are believed to be a consequence of this action. Oral administration of metoclopramide to rats for 39 days induced behavioural supersensitivity to apomorphine and enhanced specific binding of 3H-spiroperidol to striatal membranes.
These effects are induced by other neuroleptic drugs, and are associated with a potential to elicit tardive dyskinesia in man. In experimental animals, metoclopramide enhances gastrointestinal motility, increasing both resting muscle tension and the amplitude of peristaltic movements.
Metoclopramide is virtually inactive as an antagonist at the D-1 (adenylate cyclase linked) dopamine receptors, and is without potency in displacing radiolabelled ligands in receptor models designed to evaluate antipsychotic potential.
In the rat, intraventricular administration of metoclopramide and spiroperidol produce Metoclopramide Hydrochloride Injection Page 11 […]
This is not medical advice. Consult a qualified healthcare professional.
Rarely, dystonic reactions were present as stridor and dyspnea, possibly due to laryngospasm. Diphenhydramine hydrochloride or benztropine mesylate may be used to treat these adverse reactions. , antipsychotics). Parkinsonian symptoms (bradykinesia, tremor, cogwheel rigidity, mask-like facies) have occurred after starting metoclopramide, more commonly within the first 6 months, but also after longer periods.
Symptoms generally have subsided within 2 to 3 months after discontinuation of metoclopramide. Avoid metoclopramide in patients with Parkinson’s disease and other patients being treated with antiparkinsonian drugs due to potential exacerbation of symptoms.
1 ) ]. Motor restlessness (akathisia) has developed and consisted of feelings of anxiety, agitation, jitteriness, and insomnia, as well as inability to sit still, pacing, and foot tapping. If symptoms resolve, consider restarting at a lower dosage.
3 Neuroleptic Malignant Syndrome Metoclopramide may cause a potentially fatal symptom complex called neuroleptic malignant syndrome (NMS). NMS has been reported in association with metoclopramide overdosage and concomitant treatment with another drug associated with NMS.
Avoid metoclopramide in patients receiving other drugs associated with NMS, including typical and atypical antipsychotics. Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status, and manifestations of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac arrhythmias).
Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Patients with such symptoms should be evaluated immediately. , pneumonia, systemic infection) and untreated or inadequately treated extrapyramidal signs and symptoms.
Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, malignant hyperthermia, drug fever, serotonin syndrome, and primary central nervous system pathology. 1 ) ]. Intensive symptomatic treatment and medical monitoring.
Treatment of any concomitant serious medical problems for which specific treatments are available. 4 Depression Depression has occurred in metoclopramide-treated patients with and without a history of depression. Symptoms have included suicidal ideation and suicide.
Avoid metoclopramide use in patients with a history of depression. 5 Hypertension Metoclopramide may elevate blood pressure. 1 ) ]. There are also clinical reports of hypertensive crises in patients with undiagnosed pheochromocytoma. Metoclopramide is contraindicated in patients with pheochromocytoma or other catecholamine-releasing paragangliomas [ see Contraindications ( 4 ) ].
Discontinue metoclopramide in any patient with a rapid rise in blood pressure. 6 Fluid Retention Because metoclopramide produces a transient increase in plasma aldosterone, patients with cirrhosis or congestive heart failure may be at risk of developing fluid retention and volume overload.
Discontinue metoclopramide if any of these adverse reactions occur. 7 Hyperprolactinemia As with other dopamine D 2 receptor antagonists, metoclopramide elevates prolactin levels. Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion.
This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported with prolactin-elevating drugs, including metoclopramide.
Hyperprolactinemia may potentially stimulate prolactin-dependent breast cancer. 1 ) ]. 8 Effects of the Ability to Drive and Operate Machinery Metoclopramide may impair the mental and/or physical abilities required for the performance of hazardous tasks such as operating machinery or driving a motor vehicle.
, alcohol, sedatives, hypnotics, opiates, and anxiolytics). 1 ) ].